What is already known about this subject?
Introduction
Several comparative measures are used when assessing the effect of a drug or another form of intervention [1] . Whether the objective of the study is to assess the efficacy, the individual effectiveness or the population effectiveness [2] , these measures compare the rate or risk of an outcome of the disease in a group exposed to the new intervention to that in a comparison or reference group. The latter can be untreated, or receive a placebo or a reference intervention. These comparisons are usually based on the calculation of a ratio, a difference, or a more complex parameter, such as the number needed to treat [1, 3] . For example, in a paper on the efficacy of antiretroviral combination therapy [4] , results were reported as odds ratios; in another paper on the effectiveness of cell salvage [5] , results were reported as risk ratios. In both studies, several other measures of effect could easily be computed from results provided.
Often, existing measures are based on the analysis of failures. These measures, however, vary in the way they transform the same data on risk to reflect the usefulness of the new intervention. The resulting measure can convey information on the association between intervention and outcome (measure of association), or on its potential impact on the population (measure of impact). These measures can also vary in the way they are affected by the background risk measured from the reference group. A related issue is that of the ceiling effect, by which the potential gain in effect cannot be as large in absolute terms for a treatment when the background risk is small than when it is large.
In this paper, we review the formulation, interpretation, and limitations of measures of effect based on risk reduction. Following the work of Babbs [6] , we propose the attained effect or clinical result ratio, a more positive perspective in expressing the effect. This parameter is based on success, and addresses the issues of background risk and ceiling effect. We submit that the attained effect, a reformulation of the relative risk difference, may provide a useful complement to existing measures.
Methods

Background and notations
Consider a randomized controlled trial or cohort study designed to compare the risk of a given unwanted outcome under a new intervention A with that of a reference intervention B (Table 1 ). For simplicity, we assume that the time of follow-up is equal and complete for all patients in both groups, so that the risk is simply a proportion. 
Commonly used measures of effect
The existing measures of effect are either measures of association between the intervention and the risk of failure, or measures of impact of the intervention on risk. All measures are based on comparisons of r A and r B . For each measure, we provide in Table 2 the formula of the parameter, its interpretation, and its possible values under the above-mentioned assumptions. The variances of the estimators are provided in the Appendix.
B
Two existing measures of association are the risk ratio (RR) and the odds ratio (OR). These measures of effect reflect the strength of the association between type of treatment and risk of failure (RR) or odds of failure (OR). Measuring the strength of association might be useful in assessing the causal relationship between the intervention and the observed effect [7] . The OR is often abusively considered as an estimator of the population RR, but will be further away from the null hypothesis value of 1 whenever the background risk is above 10%.
The absolute risk difference (ARD) is a measure of the absolute impact of the new treatment on the risk of failure during the time of follow-up. The ARD will vary with the baseline risk, depending on the choice of the reference intervention and the targeted population. To take into account the background risk, the impact can be measured as a relative risk difference (RRD). It is a measure of the relative impact of the new intervention on the risk of failure. For a given effect, the RRD is usually constant across populations with different background risks. Although formally negative, both the ARD and RRD are often expressed positively; they are then referred as absolute and relative risk reductions [8] .
The number needed to treat (NNT) was proposed as a more direct way to convey to clinicians the magnitude of impact of a treatment [3] . The NNT, which is the inverse of the absolute value of the ARD, is a measure of the average number of patients who would 
Measures of attained effect
Our initial objectives in seeking a new measure of effect were to focus on successes rather than failures, and to take into account the ceiling effect. This effect is related to the fact that, in some circumstances, proportions of successes cannot reach 1, and will be limited by a ceiling, s t , defined as the maximum proportion of successes that one can expect, given the characteristics of the population targeted by the intervention or the nature of the outcome. This ceiling, s t , defined by Babbs [6] as the "clinically optimal or ideal outcome", can vary from s B (no expected gain in effect) to 1 (all failures are expected, at least theoretically, to be avoidable). The gain in success of a treatment, consequently, is limited by the maximum attainable gain in success, i.e., the distance between s B B B and s t .
Thus, an ideal measure of effect should take the ceiling effect in consideration, and compare the observed gain in success to this maximum attainable gain.
Consequently, we suggest the term "attained effect" (AE) to describe the parameter first defined as the "clinical result ratio" by Babbs [6] as (
. It is equal to the (observed) absolute gain in success, or absolute success difference, divided by the maximum attainable gain in success. In the best expected circumstances, where s t = 1, the
; its numerator is equal to 1 -ARD, and its denominator to r B . In that special case, the MAE is simply the positive formulation of the RRD; it is also equal to the complement to 1 of the RR. Whatever is the value set for s B t , the range of the AE, 0 to 1, is a direct reflection of the direction and size of the effect. The AE can be expressed as a percentage, and is interpreted as the proportion of possible gain in success attained by the new intervention.
Illustration
To illustrate the interpretation and relationship between measures of effectiveness, we used data from studies included in the above-mentioned meta-analyses [4, 5] . These data were extracted from published randomized controlled trials of the effectiveness of cell salvage to minimize peri-operative blood transfusion in orthopaedic patients (Table 3 ) [5] , or comparing the effect of dual and triple therapy on progression of acquired immunodeficiency syndrome or death in human immunodeficiency virus-infected patients (Table 4 ) [4] .
Results
In Table 3 , we assumed s t could not be 1, because a small proportion of patients (2 percent) would always have abundant bleeding such that blood transfusion could not be avoided.
With variations in the baseline risk of transfusion ranging between 8% and 95%, the possible gain by the evaluated treatment differed markedly from one study to the other.
Indeed, there is little room for improvement with an 8% transfusion rate, while the possibilities of improvement are huge with the 95% transfusion rate. This variability is particularly reflected in the ARD and the NTT. On the other hand, the RR, the only measure reported in the meta-analysis [5] despite its lack of relevance, RRD, and AE were less affected by this variability. Moreover, the AE expresses in the simplest form the strong effectiveness of the assessed treatment. It indicates that the gain in successes, ranging from 52 to 92%, was at least half of the maximum attainable gain. Furthermore, the MAE, which
should not be reported given the existence of a ceiling, was smaller than the AE in all studies, and could even be quite different in studies where the background risk was small.
In Table 4 , we assumed that s t could be 1, as suggested by the results of one study.
Consequently, only the MAE needed to be reported. The variation in the baseline risk was less important in this group of trials (3 to 37.5%), and the possible gain by the evaluated treatment was consequently more stable. The MAE indicates that the gain in successes was, except for one study, less than half of the maximum attainable gain, i.e. that there is still much room for improvement.
Discussion
The formal definition of parameters and their variable sensitivity to ceiling and background risk illustrates that the choice to report a parameter rather than another should always be justified. For instance, although both the RR and OR can be easily calculated from the same 2-by-2 table, they are usually not considered informative when the focus is on positive effects of drugs, discussed in this paper. Their contribution to the assessment of causality is useful only when assessing negative effects of drugs in pharmacoepidemiology studies; the choice of the parameter, in such circumstances, depends on the study design (RR for cohort studies and randomized controlled trials, OR for case-control studies).
The choice between an absolute (ARD and NNT) or a relative measure of impact (RRD and AE) is more difficult as both report important information. Both the ARD and the NNT are useful as they provide an estimation of how many events can be avoided by the application of the new treatment, but have different advantages. The NNT has been proposed as a more clinically-oriented expression of the absolute impact, but the ARD is simpler to compute.
Moreover, the interpretation of the NNT as a measure of effectiveness might be counterintuitive to readers still unfamiliar with the concept, as its value is the highest when the effectiveness is the smallest. We believe, however, that the increased use of the NNT will eventually result in the dereliction of the ARD. Formally, a mathematical and statistical approach virtually similar to the AE has first been published by Babbs [6] . In his paper, Babbs proposed the use of the "clinical result ratio", which is identical to the AE, and demonstrated how this parameter can be applied both to continuous and categorical outcomes, and integrated in a meta-analysis of randomized controlled trials. However, our paper goes beyond the original approach by Babbs by comparing the different risk measures and the relative strength and weaknesses of these alternative measures of treatment effects. Furthermore, we believe our proposed terminology of attained effect is a better reflection of what the AE (or clinical result ratio) does reveal, i.e. the proportion of possible gain in success attained by the new intervention.
From the users' perspective, we believe the AE shares the advantage of the NNT of directly reflecting the potential benefit of the intervention for targeted individuals. It also shares the advantage of the RRD, when the latter is presented as a relative risk reduction, of having the range of a simple proportion, which can be less misleading than the ranges of the RR (a logarithmic scale), or of the ARD or NNT (ranges affected by the baseline risk). Compared with the relative risk reduction, however, the AE is based on success rather than risk, which can be a more positive way to present the potential benefit, at least for some patients and health professionals.
The possibility to calculate a measure of potential benefit in circumstances where the maximum expected proportion of successes is limited provides a more generic measure of the effect of an intervention. Indeed, a ceiling of one can seem reasonable, at least theoretically, in many studies, but becomes questionable when the individuals included have characteristics incompatible with a one hundred percent success or when the followup is long and the failures of interest include outcomes such as death. For example, studies of the effectiveness of trauma care will always be limited by the fact that up to two-thirds of prehospital deaths are not preventable [9] ; in long-term follow-ups of patients treated for acquired immunodeficiency syndrome, the proportion of successes cannot be one hundred percent, given the high frequency of severe side effects [10] . One major difficulty in using the AE, however, is to justify and estimate the ceiling. In his paper [6] , Babbs proposed that, for binary outcomes, the ceiling could be set to 1, or 100% successes, in most circumstances. Whenever success is measured by survival, but a 100% survival is not realistic, the ceiling could be the predicted survival of healthy persons over the same time period [6] . Estimations of the ceiling can also be provided, whenever possible, by large cohort studies of the natural history of the disease, or by pooling estimates of background risks in previously published meta-analyses. However, Babbs suggested in his paper's discussion [6] that there could be abuse in the choice of the ceiling value, as there is some latitude in deciding what the ideal response would be. Changes in dichotomous variables to 100% survival are often obvious choices, and any other value should always be clearly justified, so that readers would be able to judge and dispute the rational of the chosen ceiling [6] . Other points are that the ceiling is always estimated with a degree of uncertainty, and that the difference between the AE and the MAE, and therefore the RRD, will be small whenever the background risk is large, as illustrated in our first example. Consequently, estimations of the AE and related parameters should always be provided with confidence intervals, and the resulting conclusions submitted to robustness analyses.
Although the focus was on simple proportions, this review of effectiveness measures applies to all comparisons of parameters with a ceiling effect. The AE, therefore, might be an appropriate measure in cohort studies of protective factors [11] , where cumulative incidences are compared, and in randomized trials with product-limit estimations of survival or event-free rates [1] . In conclusion, the AE is not meant to replace existing measures of effectiveness, nor is it formally different from the clinical result ratio proposed by Babbs [6] . It should be seen merely as a new formulation of existing ways to report results of randomized clinical trials and cohort studies. Nevertheless, we believe that all studies reporting drug effects could be limited to the NNT and either the RRD or AE, depending on the existence of a ceiling effect. An appropriate use of these parameters may improve our ability to take wise decisions regarding new drugs or other interventions.
Appendix: Variances of effect parameters
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